Water disinfection model (Dichloroacetic acid): Target Organs and Levels of Evidence for GMM-11
Toxicology Studies of Dichloroacetic Acid (CASRN 79-43-6) in Genetically Modified (FVB Tg.AC Hemizygous) Mice (Dermal and Drinking Water Studies) and Carcinogenicity Studies of Dichloroacetic Acid in Genetically Modified [B6.129-Trp53tm1Brd (N5) Haploinsufficient] Mice (Drinking Water Studies)
Chemical (Study Title) CASRN | Peer Review Date | Route/Exposure Levels | Study Laboratory |
Water disinfection model (Dichloroacetic acid) 79-43-6 | 09/27/2005 | Topical Application 0, 31.25, 125, or 500 mg/kg | Battelle Columbus Laboratory |
Levels of evidence information for Carcinogenesis and Genetic Toxicology Studies
in Tg.AC Hemizygous Mice in the Dermal Studies of Dichloroacetic Acid | Male Tg.AC Hemizygous Mice | Female Tg.AC Hemizygous Mice |
| 26 Weeks | 39 Weeks | 26 Weeks | 39 Weeks |
Neoplastic Lesions | None | - Skin (site of application): squamous cell papilloma 0/10 0/10 2/10 8/10
| None | - Skin (site of application): squamous cell papilloma 0/10 0/10 0/10 6/10
|
Non-Neoplastic Lesions | - Kidney: nephropathy
- Liver: hepatocyte cytoplasmic vacuolization; increased severity of hepatocyte cytoplasmic vacuolization
- Skin (site of application): epidermal hyperkeratosis; epidermal hyperplasia
| - Kidney: nephropathy
- Liver: hepatocyte cytoplasmic vacuolization; increased severity of hepatocyte cytoplasmic vacuolization
- Skin (site of application): epidermal hyperkeratosis; epidermal hyperplasia
| - Liver: hepatocyte cytoplasmic vacuolization; increased severity of hepatocyte cytoplasmic vacuolization
- Skin (site of application): epidermal hyperkeratosis; epidermal hyperplasia
| - Liver: hepatocyte cytoplasmic vacuolization; increased severity of hepatocyte cytoplasmic vacuolization
- Skin (site of application): epidermal hyperkeratosis; epidermal hyperplasia
|
Chemical (Study Title) CASRN | Peer Review Date | Primary Uses | Route/Exposure Levels | Study Laboratory |
Water disinfection model (Dichloroacetic acid) 79-43-6 | 09/27/2005 | Breakdown product of drinking water disinfectants, astringent, use in treatment of lactic acidosis, keratolytic agent (Merck 1989) special initiative using the transgenic mouse model for method development. Associated with tobacco: reported either as a natural component of tobacco, pyrolysis product (in tobacco smoke), or additive for one or more types of tobacco products. | Dosed-Water 0, 500, 1000, or 2000 mg/L | Battelle Columbus Laboratory |
Levels of evidence information for Carcinogenesis and Genetic Toxicology Studies
in Tg.AC Hemizygous Mice in the Drinking Water Studies of Dichloroacetic Acid | Male Tg.AC Hemizygous Mice | Female Tg.AC Hemizygous Mice |
| 26 Weeks | 41 Weeks | 26 Weeks | 41 Weeks |
Neoplastic Lesions | - Lung: alveolar/bronchiolar carcinoma 0/15 0/15 1/15 0/15
| - Lung: alveolar/bronchiolar adenoma 1/10 2/10 7/10 3/10
| - Lung: alveolar/bronchiolar carcinoma 0/15 1/15 0/15 1/15
| - Lung: alveolar/bronchiolar adenoma 0/10 0/10 0/10 2/10
|
Non-Neoplastic Lesions | - Liver: hepatocyte cytoplasmic vacuolization; increased severity of hepatocyte cytoplasmic vacuolization
| - Liver: hepatocyte cytoplasmic vacuolization; increased severity of hepatocyte cytoplasmic vacuolization
| - Liver: hepatocyte cytoplasmic vacuolization; increased severity of hepatocyte cytoplasmic vacuolization
| - Liver: hepatocyte cytoplasmic vacuolization; increased severity of hepatocyte cytoplasmic vacuolization
|
Levels of evidence information for Carcinogenesis and Genetic Toxicology Studies
in p53 Haploinsufficient Mice in the Drinking Water Studies of Dichloroacetic Acid | Male p53 Haploinsufficient Mice | Female p53 Haploinsufficient Mice |
| 26 Weeks | 41 Weeks | 26 Weeks | 41 Weeks |
Levels of Evidence | No Evidence | No Evidence | No Evidence | No Evidence |
Neoplastic Lesions | None | None | None | None |
Non-Neoplastic Lesions | - Liver: hepatocyte cytoplasmic vacuolization; increased severity of hepatocyte cytoplasmic vacuolization
| - Liver: hepatocyte cytoplasmic vacuolization; increased severity of hepatocyte cytoplasmic vacuolization
| - Liver: hepatocyte cytoplasmic vacuolization; increased severity of hepatocyte cytoplasmic vacuolization
| - Liver: hepatocyte cytoplasmic vacuolization; increased severity of hepatocyte cytoplasmic vacuolization
|